89bio

Executive Summary

89bio is a clinical-stage biopharmaceutical company developing pegozafermin, a glycopegylated FGF21 analog, for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Based on Phase 2 data, pegozafermin has demonstrated favorable efficacy and safety profiles, including significant reductions in liver fat and improvements in metabolic parameters. The company is advancing toward pivotal trials, with a Phase 3 MASH study expected to initiate soon. 89bio's differentiated mechanism and promising clinical results position it as a potential leader in the MASH space, though it remains private with limited financial visibility. Key upcoming catalysts include the start of Phase 3 MASH enrollment, further SHTG data, and potential partnership or financing events.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 3 MASH trial (ENLIGHTEN-Fibrosis)80% success
• Q1 2027Phase 2b SHTG topline data from ongoing trial70% success
• H2 2027Strategic partnership for ex-U.S. commercialization rights60% success